merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Eli Lilly's vials are positioned as a safer, FDA-approved alternative to compounded drugs, which lack the same level of oversight.</answer>
<question_number>2</question_number>
<answer>LillyDirect offers a similar telehealth model, delivering Zepbound vials directly to patients and bypassing the need for third-party telehealth companies.</answer>
<question_number>3</question_number>
<answer>Compounded drugs are subject to less oversight and may pose risks related to safety, quality, and effectiveness.</answer>
<question_number>4</question_number>
<answer>Eli Lilly aims to attract customers using cheaper compounded alternatives while maintaining control over the market for lower doses.</answer>
<question_number>5</question_number>
<answer>Tirzepatide's presence on the FDA shortage list allows compounding pharmacies to legally produce alternatives, but Lilly seeks to eliminate this space once the shortage ends.</answer>
<question_number>6</question_number>
<answer>N/A</answer>
<question_number>7</question_number>
<answer>Medicare's refusal to cover weight-loss drugs may drive older patients to seek cheaper, potentially riskier options like compounded medications or switch to Zepbound vials.</answer>
<question_number>8</question_number>
<answer>Eli Lilly's vials are framed as a safer, regulated option, which could shift patient trust away from compounded versions.</answer>
<question_number>9</question_number>
<answer>Tirzepatide is listed by the FDA as "in shortage," allowing legal production of compounded alternatives.</answer>
<question_number>10</question_number>
<answer>Eli Lilly is offering lower-cost, FDA-approved vials to compete directly with compounded drugs, signaling an intent to reclaim market share.</answer>